A Phase 4 interventional study of tigecycline and ceftriaxone sodium + metronidazole in Appendicitis, Cholecystitis and Cross Infection, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 66 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-02-25.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Appendicitis with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Appendicitis · United States.
Among the 78 studies in Appendicitis with a site in United States, this one is the 9th largest by enrollment of the 59 interventional ones that give a count, is one of 2 that started in 2005, is one of 10 in phase 4, and was the 1st registered.
421 studies on the registry are indexed under Appendicitis; 67 are open to participants now.
Browse Appendicitis studies →6 of the 78 studies in Appendicitis with a site in United States are open now. Recruiting first, the newest first:
True Bearing Diagnostics, Inc. · Sites in United States
Ages 7+ · Healthy volunteers
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
Ann & Robert H Lurie Children's Hospital of Chicago · Sites in United States
Ages 3–18
Yale University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Appendicitis studies recruiting now, 18 (46%) set no upper age limit and 19 (49%) stop at 75 or younger; 23 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 3 · Phase 4 10
First in 2003; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 467 is above the median of 116 across 254 interventional studies indexed under Appendicitis.
Median enrollment 98 across the 59 interventional studies, 174 across the 19 observational. Of the 58 that completed or were terminated, 26 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 78 have an industry lead sponsor. The 10 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
Pfizer has 3 studies filed under Appendicitis — fewer than ten, so there is no comparison to draw.
3 of the studies in Appendicitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04039750Prisma Health-UpstateUse of Antibiotic Irrigation to Decrease Wound Infections in Pediatric Perforated Appendicitis | 2026-12 |
| NCT07579312True Bearing Diagnostics, Inc.Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL Study | 2027-04 |
| NCT06395636Ann & Robert H Lurie Children's Hospital of ChicagoEarly Detection of Infection Using the Fitbit in Pediatric Surgical Patients | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 78 studies in Appendicitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 3b/4 randomized, open-label, comparative, multicenter study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI (Complicated Intra-Abdominal Infection). Subjects with clinical signs and symptoms of cIAI will be included for enrollment. Subjects will be stratified at randomization for Acute Physiologic and Chronic Health Evaluation scale (APACHE II) score \< 10 and > 10. Subjects will be followed for efficacy through the test-of-cure assessment. Safety evaluations will occur through the treatment and post-treatment periods and continue through resolution or stability of the adverse event(s).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: tigecycline
Drug: ceftriaxone sodium + metronidazole
every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
Drug pages: Ceftriaxone · Metronidazole
Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
Number of Clinically Evaluable Patients With Clinical Response of Cure at Test-of-Cure (TOC) Visit.
The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection.
Time frame: 10-21 days after the last dose of test article
Number of Microbiologically Evaluable Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit.
The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection.
Time frame: 10-21 days after the last dose of test article
Number of Patients by Microbiologic Response at Test-of-Cure (TOC) Visit.
Microbiologic response assessed at patient level was combined microbiologic responses for all baseline isolates identified in intra-abdominal/blood cultures. Eradication=baseline isolate not recovered from primary infection site/blood; Presumed Eradication=no material available for culture but response was cure; Persistence=baseline isolate recovered from primary infection site/blood; Presumed Persistence=no material available for culture but response was failure; Superinfection=culture from primary infection site was positive for new isolate not identified at baseline \& response was failure.
Time frame: 10-21 days after the last dose of test article
Subjects were recruited worldwide from September 2005 to February 2008.
| Milestone | Tigecycline | Ceftriaxone Sodium + Metronidazole |
|---|---|---|
| Started | 236 | 231 |
| Completed | 215 | 215 |
| Not completed | 21 | 16 |
| Withdrew: Lost to follow-up | 9 | 9 |
| Withdrew: Withdrawal by subject | 6 | 3 |
| Withdrew: Protocol deviation | 3 | 2 |
| Withdrew: Death | 3 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection.
| participants | Tigecycline | Ceftriaxone Sodium + Metronidazole |
|---|---|---|
| Number of Clinically Evaluable Patients With Clinical Response of Cure at Test-of-Cure (TOC) Visit. | 133 | 139 |
The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection.
| participants | Tigecycline | Ceftriaxone Sodium + Metronidazole |
|---|---|---|
| Number of Microbiologically Evaluable Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit. | 91 | 96 |
Microbiologic response assessed at patient level was combined microbiologic responses for all baseline isolates identified in intra-abdominal/blood cultures. Eradication=baseline isolate not recovered from primary infection site/blood; Presumed Eradication=no material available for culture but response was cure; Persistence=baseline isolate recovered from primary infection site/blood; Presumed Persistence=no material available for culture but response was failure; Superinfection=culture from primary infection site was positive for new isolate not identified at baseline \& response was failure.
| participants | Tigecycline | Ceftriaxone Sodium + Metronidazole |
|---|---|---|
| Eradication and presumed eradication | 94 | 98 |
| Persistence and presumed persistence | 44 | 39 |
| Superinfection | 7 | 3 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tigecycline | — | — | — |
| Ceftriaxone Sodium + Metronidazole | — | — | — |
| Event | Tigecycline | Ceftriaxone Sodium + Metronidazole |
|---|---|---|
| AbscessGeneral disorders | 18/236 | 13/231 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/236 | 5/231 |
| InfectionGeneral disorders | 3/236 | 4/231 |
| LymphoceleGeneral disorders | 0/236 | 4/231 |
| Abdominal painGeneral disorders | 3/236 | 3/231 |
| SepsisGeneral disorders | 0/236 | 3/231 |
| IleusGastrointestinal disorders | 3/236 | 3/231 |
| Intestinal obstructionGastrointestinal disorders | 2/236 | 3/231 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 1/236 | 3/231 |
| Pulmonary embolusCardiac disorders | 3/236 | 1/231 |
| Event | Tigecycline | Ceftriaxone Sodium + Metronidazole |
|---|---|---|
| NauseaGastrointestinal disorders | 91/236 | 64/231 |
| VomitingGastrointestinal disorders | 55/236 | 41/231 |
| DiarrheaGastrointestinal disorders | 42/236 | 40/231 |
| InsominaNervous system disorders | 23/236 | 24/231 |
| AbscessGeneral disorders | 23/236 | 15/231 |
| HeadacheGeneral disorders | 14/236 | 22/231 |
| Abdominal painGeneral disorders | 22/236 | 16/231 |
| HypokalemiaMetabolism and nutrition disorders | 16/236 | 21/231 |
| LeukocytosisBlood and lymphatic system disorders | 19/236 | 4/231 |
| FeverGeneral disorders | 17/236 | 18/231 |
| Age Continuous(years) | Tigecycline | Ceftriaxone Sodium + Metronidazole | Total |
|---|---|---|---|
| Mean | 48.17 ± 18.05 | 48.79 ± 17.46 | 48.48 ± 17.74 |
| Sex: Female, Male(Participants) | Tigecycline | Ceftriaxone Sodium + Metronidazole | Total |
|---|---|---|---|
| Female | 93 | 72 | 165 |
| Male | 143 | 159 | 302 |
| Region of Enrollment(participants) | Tigecycline | Ceftriaxone Sodium + Metronidazole | Total |
|---|---|---|---|
| United States | 163 | 169 | 332 |
| Mexico | 1 | 0 | 1 |
| Canada | 39 | 25 | 64 |
| Argentina | 4 | 2 | 6 |
| Brazil | 23 | 23 | 46 |
| Chile | 6 | 12 | 18 |
The record gives a start of Sep 2005, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tigecycline · Ceftriaxone · Metronidazole
Wyeth is now a wholly owned subsidiary of Pfizer →